ZVIA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zevia PBC is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is unwilling to wait for a better entry. The stock is showing short-term strength, but it is already overbought and lacks strong fundamental or catalyst support to justify an immediate long-term purchase. Best decision: hold and wait.
ZVIA is in a short-term rebound phase with the MACD histogram positive and expanding, which supports bullish momentum. However, RSI_6 is extremely high at 81.237, signaling overbought conditions. The stock is trading at 1.66, above the pivot at 1.402 and near the first resistance zone at 1.598, with the next resistance at 1.72. Moving averages are converging, which suggests the trend is not yet firmly established. Overall, the chart looks extended after a sharp move, so this is not an attractive new long-term entry right now.
Recent analyst commentary is still constructive overall despite target cuts. Telsey maintained an Outperform rating and pointed to strong Q1 volume gains of 20.4% and continued turnaround progress, supported by higher 2026 sales growth guidance. Options positioning is also bullish, which suggests traders are leaning positive on near-term upside.
There was no news in the recent week, so there is no fresh event-driven catalyst. The stock is overbought technically, and moving averages are only converging rather than confirming a durable uptrend. Analyst price targets have been cut across multiple firms, including Morgan Stanley, Telsey, and Goldman Sachs, and Morgan Stanley still rates the stock Equal Weight. The company also lowered FY26 adjusted EBITDA guidance due to higher tariffs and fuel costs. Hedge funds and insiders are neutral, and there is no recent congress or influential figure trading activity.
Latest quarter season: Q1. The company reported better-than-expected Q1 results, with strong volume growth of 20.4%. That is a positive sign for top-line momentum and turnaround execution. However, the company lowered FY26 adjusted EBITDA guidance because of higher-than-expected tariffs and fuel costs, which weakens the earnings outlook even though sales growth guidance improved.
Analyst sentiment is mixed to mildly positive. Telsey Advisory remained Outperform, but lowered its price target to $3 from $5 after Q1 results, citing strong volume growth and ongoing turnaround progress. Morgan Stanley cut its target to $1.75 from $2.90 and kept Equal Weight after mixed Q4 results and below-consensus FY26 guidance. Goldman Sachs also lowered its target to $3 from $3.50 and stayed Neutral. Overall, Wall Street sees turnaround potential, but the repeated target cuts show declining confidence in the near-term valuation upside.
